S1P receptor modulators for treating relasping-remitting multiple sclerosis

CAFC
  • US 9,187,405 B2
  • Filed: 04/21/2014
  • Issued: 11/17/2015
  • Est. Priority Date: 06/27/2006
  • Status: Active Grant
First Claim
Patent Images

1. A method for reducing or preventing or alleviating relapses in Relapsing-Remitting multiple sclerosis in a subject in need thereof, comprising orally administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×